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Aims We sought to analyse quality of life (QoL) measures derived from two questionnaires widely used in clinical trials,
the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EuroQoL 5 dimensions (EQ-5D), and to compare
their prognostic value in men and women with heart failure and reduced ejection fraction (HFrEF).
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Methods
and results
From the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) we compared KCCQ
and EQ-5D at baseline and after 9 months in 1276 men and 373 women with new-onset or worsening symptoms
of HFrEF, who were sub-optimally treated and in whom there was an anticipated up-titration of guideline-derived
medical therapies. Women had significantly worse baseline QoL (median) as compared with men, both when assessed
with KCCQ overall score (KCCQ-OS, 44 vs. 53, P < 0.001) and EQ-5D utility score (0.62 vs. 0.73, P < 0.001). QoL
improved equally in women and men at follow-up. All summary measures of QoL were independently associated with
all-cause mortality, with KCCQ-OS showing the most remarkable association with mortality up to 1 year compared
to the EQ-5D scores (C-statistic 0.650 for KCCQ-OS vs. 0.633 and 0.599 for EQ-5D utility score and EQ-5D visual
analogue scale, respectively). QoL was associated with all outcomes analysed, both in men and women (all P for
interaction with sex >0.2).
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Conclusion Amongst patients with HFrEF, women reported significantly worse QoL than men. QoL was independently associated
with subsequent outcome, similarly in men and women. The KCCQ in general, and the KCCQ-OS in particular,
showed the strongest independent association with outcome.
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Graphical Abstract
Sex differences in quality of life, in its relationship with outcomes, and predictive ability of different quality of life measures towards outcome.
BIOSTAT-CHF, BIOlogy Study to TAilored Treatment in Chronic Heart Failure; EQ-5D, EuroQoL 5 dimensions; KCCQ, Kansas City Cardiomyopathy
Questionnaire; OS, overall score; US, utility score; VAS, visual analogue scale.
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Introduction
Patients with heart failure (HF) suffer from debilitating physical
symptoms, frequently associated with depressive symptoms, anxi-
ety, and cognitive disorders that further affect their daily function
and quality of life (QoL).1 Notably, patients with HF generally have
a poor QoL, which is much lower compared to healthy individuals
and even to patients with other chronic illnesses.1
Previous analyses of trials and registries in HF highlighted sev-
eral differences between men and women with regard to clinical
features and event rates.2 Of particular interest is the observed
sex difference in QoL, with women experiencing poorer QoL
and greater perceived disability as compared with men.3,4 Lower
QoL in HF with reduced ejection fraction (HFrEF) is associated
with increased hospitalizations and mortality.5–7 However, sex
differences in the relationship of QoL to outcomes require further
investigation.
Tools aimed at assessing patients’ perception of their health
status are widely used in research, and potentially approvable
endpoints in medication development.8 Various QoL surveys have
been used for patients with HF, both generic and disease-specific.9
The EuroQol 5 dimensions (EQ-5D) questionnaire is a widely used,


































. whereas the Kansas City Cardiomyopathy Questionnaire (KCCQ)
was specifically designed and validated for health-related QoL
assessment in patients with HF.11 Head-to-head comparisons on
the discriminative power and prognostic value of these two QoL
assessment methods are limited.
We therefore sought to analyse sex differences in QoL as
assessed with two widely used QoL questionnaires, and to
assess whether there are sex differences in QoL variations after
up-titration of HF therapies. Moreover, we analysed the relation-
ship between different measures of QoL and outcomes, testing for
the interaction of sex in this association. Finally, we compared the
predictive ability of different QoL measures towards outcome.
Methods
Patient population
We studied patients from the index cohort of the BIOlogy Study to
TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), whose
design has been described in detail elsewhere.12 Briefly, BIOSTAT-CHF
was a multicentre, multinational, prospective, observational study. The
index cohort included 2516 patients enrolled from 11 European coun-
tries between December 2010 and December 2012. To be enrolled in
the study patients had to comply with protocol specified criteria.12 The
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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main inclusion criteria were signs and/or symptoms of new-onset or
worsening HF and sub-optimal (≤50% target dose; online supplemen-
tary Table S1) treatment with angiotensin-converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARBs) and/or beta-blockers,
with anticipated initiation or up-titration of these drugs according to
the target doses recommended by the European Society of Cardi-
ology (ESC) guidelines13,14 (online supplementary Table S1). Patients
could be enrolled either as inpatients or from outpatient clinics. Inves-
tigators were encouraged to optimize treatment with ACEi/ARB and
beta-blockers during the first 3 months of the study.
All patients provided written informed consent to participate in the
study and BIOSTAT-CHF complied with the Declaration of Helsinki.
The study was approved by the ethics committees of the participating
centres.
Study procedures and quality of life
assessment
The first study assessment was performed at baseline, then a second
visit was planned after 9 months. Medical history, current medication,
and physical examination were recorded at both visits, and blood
and urine samples were collected for subsequent analyses. QoL was
assessed with EQ-5D and KCCQ, both at baseline and 9-month visits;
details on the questionnaires are described in the online supplemen-
tary Methods. Six-minute walk test (6MWT) was also performed at
both visits.8
In our analyses, only patients with HFrEF, thus with a left ventricular
ejection fraction <40%, were included (n = 1819). Patients who did
not complete both KCCQ and EQ-5D questionnaires at baseline were
also excluded from the main analyses (n = 170). For the limited set of
analyses considering the variation of QoL parameters at follow-up, we
also excluded patients who did not complete both KCCQ and EQ-5D
questionnaires at 9 months (n = 407). A flow diagram is displayed in
online supplementary Figure S1.
Follow-up and outcomes
After the second study visit, patients were prospectively followed by
ambulatory visits or telephone calls at 6-month intervals until the end
of the study, in April 2015. The protocol of BIOSTAT-CHF used clear
endpoint definitions, a structured case report form, and source data of
all sites were closely monitored. All deaths and hospitalizations were
recorded. The adjudication of HF hospitalization was performed by the
treating physician. After the trial has ended, all medical reports of the
deadly event were read and adjudicated by an independent committee
of cardiologists. Median follow-up was 21 months [interquartile range
(IQR) 11–32 months].12
Statistical analysis
Normally distributed continuous variables are presented as means ±
standard deviation and non-normally distributed variables as median
(IQR). Categorical variables are reported as numbers with percent-
ages. Baseline clinical parameters were compared between men and
women, and between patients with quartiles of KCCQ overall score
(KCCQ-OS). Group comparisons were made using ANOVA, Student’s
t-tests, Chi-square tests and Mann–Whitney U tests as appropriate.
QoL variation between different timepoints was compared using paired
samples t-tests. Shift analysis was also performed to check for sex dif-



















































































.. 3-month HF therapies were also compared using shift analysis (details
in online supplementary Methods).
Univariable and multivariable Cox proportional hazard models were
used to evaluate the impact of QoL overall measures [KCCQ-OS;
EQ-5D utility score (US), US; EQ-5D visual analogue scale (VAS)] on
mortality, HF hospitalization and the composite outcome (death and/or
HF hospitalization). Hazard ratios are expressed as mean and 95%
confidence interval (CI). To account for potential confounding factors,
the previously published multivariable risk models of BIOSTAT-CHF
for mortality, HF hospitalization or the composite outcome at 1 year
were used, as appropriate, for adjustment in the multivariable Cox and
competing-risk regression models.15 The covariates in each model are
displayed in the online supplementary Methods. QoL measures were
modelled as continuous variables: 5 point-change units for KCCQ-OS
and EQ-5D VAS, and 0.1 point-change units for EQ-5D US were
considered because of clinical meaning and comparable magnitude.16
Univariable and multivariable Cox proportional hazard models were
obtained for the total study population and for men and women
separately. Additionally, for all relationships between QoL measures
and outcome, interaction with sex was tested, and effect plots stratified
by sex were obtained for immediate results visualization.
To compare the impact of each QoL measure on outcomes, between
univariable Cox models the change in C-statistics was computed,
time-dependent receiver operating characteristic (ROC) curves were
plotted to study the strength of the association of each QoL measure
to outcome over time, and net reclassification improvement (NRI)
was calculated (details in online supplementary Methods). We finally
tested the additive ability of each QoL measure to reclassify risk of
each outcome beyond the BIOSTAT-CHF risk models, by examining
categorical NRI.
Statistical analyses were performed using R, A Language and Envi-
ronment for Statistical Computing, version 3.5.1 (R Foundation for
Statistical Computing, Vienna, Austria), and IBM SPSS Statistics for
Windows, version 23.0.0.3 (IBM Corp., Armonk, NY, USA).
Results
Clinical characteristics
A total of 1649 patients were studied, 373 (23%) of whom were
women. Baseline characteristics of men and women are dis-
played in Table 1 and online supplementary Table S2. At baseline,
women were older (71 vs. 66 years, P< 0.001), had slightly higher
left ventricular ejection fraction (29% vs. 27%, P< 0.001), and
were less likely to have an ischaemic HF aetiology (49% vs. 64%,
P< 0.001). Clinical signs and symptoms of HF and vitals were
fairly similar between men and women. Notably, there was no
significant sex difference in New York Heart Association (NYHA)
class (P = 0.688), median HF duration (4 vs. 2 months, P = 0.434),
and N-terminal pro-B-type natriuretic peptide (NT-proBNP)
(P = 0.076). Women were less likely to have most comorbidi-
ties, especially atherothrombotic disease in general. Baseline HF
medications were similar in men and women, except for mineralo-
corticoid receptor antagonists (MRAs) and digoxin, that were more
often prescribed in men (59% vs. 49%, P< 0.001% and 21% vs. 13%,
P = 0.002, respectively). There was no significant sex difference
in the fraction of target dose of ACEi/ARB or beta-blockers
both at baseline and after the up-titration phase (online
supplementary Figure S5 and S6).
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics stratified by sex
Men Women P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No. of subjects 1276 373
Demographics
Age, years 66±12 71±12 <0.001
Race, n (%) 0.013
Caucasian 1261 (98.8) 367 (98.4)
Other 15 (1.1) 6 (1.6)
BMI, kg/m2 27.80 (5.19) 27.11 (5.58) 0.027
Weight, kg 85±18 72± 16 <0.001
Height, cm 174± 8 162± 7 <0.001
Clinical profile
NYHA class, n (%) 0.688
I 31 (2.5) 6 (1.6)
II 470 (37.5) 131 (35.8)
III 611 (48.8) 188 (51.4)
IV 140 (11.2) 41 (11.2)
LVEF, % 26.8± 7 28.9± 6.3 <0.001
Systolic blood pressure, mmHg 122.4± 20.0 126.5± 23.4 0.001
Diastolic blood pressure, mmHg 75.6±12.2 74.8±13.5 0.280
Heart rate, bpm 79.6±18.8 80.7±18.3 0.352
Type of visit (%) 0.695
Outpatient 482 (37.8) 139 (37.2)
Inpatient 794 (62.2) 234 (62.7)
HF history
Months since first diagnosis 3.70 [0.17–42.85] 1.90 [0.10–10.40] 0.434
HF aetiology, n (%)
Ischaemic 734 (63.6) 158 (49.4) <0.001
Valvular 498 (39) 145 (38.9) 0.320
Past HF hospitalization 431 (33.8) 117 (31.4) 0.420
Medical history, n (%)
Hypertension 744 (58.3) 239 (64.1) 0.053
Atrial fibrillation 558 (43.7) 131 (35.1) 0.004
Myocardial infarction 530 (41.5) 105 (28.2) <0.001
Diabetes mellitus 412 (32.3) 103 (27.6) 0.099
COPD 230 (18.0) 44 (11.8) 0.006
Peripheral artery disease 135 (10.6) 22 (5.9) 0.009
Stroke 109 (8.5) 30 (8.0) 0.842
Medication, n (%)
ACEi or ARBs 962 (75.4) 268 (71.8) 0.189
Beta-blockers 1088 (85.3) 305 (81.8) 0.119
MRAs 752 (58.9) 181 (48.5) <0.001
Laboratory
Haemoglobin, g/dL 13.80 [12.30–14.90] 12.80 [11.75–13.72] <0.001
Creatinine, mg/dL 1.20 [1.00–1.50] 1.00 [0.81–1.23] <0.001
Urea, mmol/L 12.14 [8.00–19.99] 9.70 [7.20–16.00] <0.001
Sodium, mmol/L 140.00 [137.00–142.00] 140.00 [138.00–142.00] 0.064
Potassium, mmol/L 4.30 [4.00–4.60] 4.20 [3.80–4.60] 0.002
NT-proBNP, ng/L 4148.00 [2288.00–8220.00] 4706.50 [2471.00–9992.00] 0.076
Continuous variables are presented as means± standard deviation when normally distributed, or median [interquartile range] for non-normally distributed variables. Categorical
variables are shown as n (%).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HF, heart failure; LVEF,
left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
Sex differences in quality of life
Distributions of overall QoL measures at baseline and their change





.. QoL than men as assessed with KCCQ-OS (44 vs. 53, P< 0.001)
and EQ-5D US (0.6 vs. 0.7, P< 0.001), with a similar tendency
for EQ-5D VAS (50 vs. 55, P = 0.062). Similarly, women showed
worse exercise capacity as assessed with 6MWT (180 vs. 281 m,
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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P< 0.001; online supplementary Table S2). Baseline KCCQ domain
scores and answers to EQ-5D questions in men and women
are displayed in Figure 2. Upon enrolment, women reported a
significantly higher burden of limitation as captured by six (out
of seven) KCCQ domains and all the five dimensions in the
EQ-5D (Figure 2B). Notably, answers to KCCQ items show that
the sex difference in perceived physical limitation increased as the
considered activities became more demanding, with fatigue being
the most limiting symptom in women as compared with men, and
all social activities being more affected by HF symptoms in women
(online supplementary Figure S2).
After 9 months, all QoL summary measures significantly
improved in the total population, and in men and women sep-
arately (all P< 0.001; online supplementary Table S5). Likewise,
6MWT distance improved in the total population, and in men and
women separately (all P< 0.001; online supplementary Table S5).
The absolute change in QoL measures, more pronounced in
KCCQ-OS and EQ-5D VAS, was similar in men and women
(Figure 1). The magnitude of change in any QoL score at 9 months
was neither dependent on sex (all P> 0.1) nor on the fraction of
the target dose of ACEi/ARB or beta-blocker achieved after the
up-titration period (all P> 0.05), with large QoL variability among
each group (online supplementary Tables S3 and S4, and Figure S7).
In particular, KCCQ single answers and domain scores, and EQ-5D
items at 9 months showed an improvement in QoL which was
consistent across all the considered areas, and was slightly more
pronounced in symptoms and physical limitation, similarly in men
and women (online supplementary Table S5, and Figures S3 and S4).
Quality of life and outcome
Table 2 shows the association of baseline QoL measures with out-
comes. Univariable Cox regression showed that all QoL measures
were significantly associated with all-cause mortality and the com-
posite outcome in the entire study population and also in both
sexes separately. After adjustment, all QoL measures were inde-
pendently associated with mortality and the composite outcome in
the total population and in men, with a similar tendency in women
(Table 2). When considering HF hospitalization, in univariable Cox
regression all QoL measures were significantly associated with both
outcomes in the total population and in men, whereas in women
KCCQ-OS was the only QoL measure significantly associated with
this outcome (Table 2). In multivariable analyses, only KCCQ-OS
and EQ-5D VAS were independently associated with HF hospital-
ization in the entire population and in men (Table 2). As for the
other analysed outcomes, hazard ratios showed a similar tendency
in women as compared with men. For all outcomes, there was no
significant QoL-by-sex interaction (all P> 0.2). Additionally, effect
plots showed similar predicted probability in men and women for
all considered outcomes across the levels of QoL measures (online
supplementary Figures S8–S10).
The 6MWT showed a significant association with all-cause
mortality in the total population, and in men and women sep-
arately at univariable Cox regression; whilst only in the total
population and in men after adjustment for the BIOSTAT-CHF



















































































.. outcomes were considered, 6MWT showed a modest association
with outcome only at univariable analysis (online supplemen-
tary Table S6). Interestingly, a significant interaction of sex in
the association between 6MWT and all-cause mortality was
observed, with women showing lower risk of death than men for
similar 6MWT values (P for interaction: unadjusted 0.02, adjusted
0.046).
Univariable predictive power of KCCQ-OS for all-cause mor-
tality was significantly better than the one of EQ-5D VAS, but not
EQ-5D US, when models were compared using C-statistic (0.650
vs. 0.599 and 0.633, respectively, P< 0.001 and P = 0.185) and
NRI (0.268, 95% CI 0.123–0.383 and 0.089, 95% CI −0.023 to
0.224, respectively; online supplementary Table S8). Conversely,
univariable predictive power of KCCQ-OS towards HF hospital-
ization and the composite outcome was significantly better than
those of both EQ-5D-derived measures, both when compared
using C-statistic (all P< 0.001; Table 3) and NRI (online supple-
mentary Table S8). Using time-dependent ROC curves, KCCQ-OS
resulted the strongest univariable predictor of mortality up to
1 year (Figure 3A, and online supplementary Table S7A), and of HF
hospitalization and the composite outcome up to 2 years (Figure 3B
and 3C, and online supplementary Table S7B and S7C). For all out-
comes, adding any QoL measure did not significantly improve NRI
compared to the corresponding BIOSTAT-CHF risk model (online
supplementary Table S8).
Discussion
Assessment of QoL is an important tool that integrates physical
examination with a comprehensive, reliable and reproducible char-
acterization of HF patients’ experience with their own illness.9,17
QoL measures are useful for HF surveillance and prognostication,
and constitute potential outcomes to support labelling claims for
new drugs and devices.1,17 Acknowledgement of sex differences
in QoL and of their clinical impact is therefore important to cor-
rectly interpret QoL data. In our analysis of 1649 patients with
HFrEF from 11 European countries, we confirmed that women
with HFrEF report worse QoL than men; however, QoL equally
improved in men and women during follow-up. QoL measures were
independent predictors of mortality, HF hospitalization, and the
combined outcome with no significant interaction of sex. Despite
KCCQ-OS showed the best predictive value for all outcomes,
there was no significant added prognostic value of QoL as assessed
with this score to the predictive ability of the BIOSTAT-CHF risk
models15 (Graphical Abstract).
The larger impact of HFrEF on QoL in women confirms pre-
vious findings,3,4 and is concordant with the worse performance
of women in 6MWT, an objective measure of exercise capacity.
We observed a large (9 point) sex difference in KCCQ-OS, with
EQ-5D also capturing the worse QoL perceived by women, partic-
ularly when scored with EQ-5D US. Among KCCQ domains, the
most remarkable sex differences were a 17 point difference in the
physical limitation score and a 12 point difference in the social lim-
itation score. The answers to EQ-5D questions also revealed that
HF impacted more on women’s health status also psychologically,
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Sex differences in the distribution of baseline quality of life measures (A–C), and their difference between baseline and 9 months
(D–F), boxplots showing median values and interquartile ranges. EQ-5D, EuroQoL 5 dimensions; KCCQ, Kansas City Cardiomyopathy
Questionnaire.
with more than 60% of women reporting moderate to severe anx-
iety or depression at baseline. These differences were observed
even though physician-assessed signs and symptoms of HF were
fairly similar in men and women, and most comorbidities were
more prevalent in men. Other markers of HF severity, including
NT-proBNP and HF hospitalizations in the year before enrolment,










. though women were older than men in our study population. This
greater perceived physical and psychological disability of women
despite similar physician-assessed signs and symptoms of HF high-
lights the importance of QoL assessment for a comprehensive HF
patient characterization, while future studies may address these dif-
ferences in evaluating potential personalized therapeutic strategies
for women with HFrEF.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Sex differences in the baseline distribution of (A) the Kansas City Cardiomyopathy Questionnaire (KCCQ) domain scores (boxplot,
medians and interquartile ranges), and (B) the answers to EuroQol 5 dimensions (EQ-5D) items (cumulative percentages).
At 9-month follow-up visit, both men and women showed a
similar improvement in QoL, especially marked as assessed with
KCCQ, regardless of sex or the fraction of target dose achieved,
and consistent across all KCCQ domains and EQ-5D items. Several
are the potential explanations for this overall QoL trend over
time. First, patients in BIOSTAT-CHF were enrolled either with de
novo or worsening HF symptoms,12 thus maximizing the chances











. enrolled in BIOSTAT-CHF might have benefited from the close
follow-up entailed by the participation in a clinical study. However,
QoL change over time was also evaluated in several of the pivotal
trials of ACEi,18,19 ARB20,21 and beta-blockers22,23 in HFrEF, showing
an overall improvement in QoL with these drugs as compared to
placebo in stable, symptomatic HFrEF patients. The QoL metrics
used in these studies were heterogeneous and mainly HF-specific,
and none of these analyses evaluated sex differences in QoL
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Association of baseline quality of life measures with mortality, heart failure hospitalization, and mortality
and/or heart failure hospitalization





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
KCCQ-OS
Total 1649 371 (22.5) 0.89 (0.87–0.92) <0.001 0.95 (0.92–0.97) <0.001
Men 1276 112 (23.4) 0.90 (0.87–0.92) <0.001 0.94 (0.91–0.97) <0.001
Women 373 33 (19.3) 0.86 (0.81–0.92) <0.001 0.94 (0.88–1.00) 0.078
EQ-5D VAS
Total 1649 371 (22.5) 0.94 (0.91–0.96) <0.001 0.97 (0.93–0.99) 0.009
Men 1276 112 (23.4) 0.94 (0.92–0.96) <0.001 0.97 (0.94–1.00) 0.024
Women 373 33 (19.3) 0.92 (0.87–0.97) 0.002 0.96 (0.91–1.02) 0.167
EQ-5D US
Total 1649 371 (22.5) 0.88 (0.86–0.91) <0.001 0.94 (0.90–0.96) <0.001
Men 1276 112 (23.4) 0.87 (0.85–0.9) <0.001 0.92 (0.89–0.96) <0.001
Women 373 33 (19.3) 0.88 (0.82–0.94) <0.001 0.96 (0.89–1.02) 0.229
Heart failure hospitalization
KCCQ-OS
Total 1649 374 (22.7) 0.9 (0.88–0.93) <0.001 0.94 (0.92–0.97) <0.001
Men 1276 293 (23) 0.90 (0.88–0.92) <0.001 0.94 (0.91–0.96) <0.001
Women 373 81 (21.7) 0.92 (0.87–0.97) 0.003 0.96 (0.90–1.01) 0.145
EQ-5D VAS
Total 1649 374 (22.7) 0.95 (0.93–0.97) <0.001 0.97 (0.95–0.99) 0.016
Men 1276 293 (23) 0.95 (0.92–0.97) <0.001 0.97 (0.94–1.00) 0.022
Women 373 81 (21.7) 0.96 (0.91–1.00) 0.094 0.97 (0.92–1.03) 0.415
EQ-5D US
Total 1649 374 (22.7) 0.93 (0.90–0.96) <0.001 0.97 (0.94–1.00) 0.079
Men 1276 293 (23) 0.92 (0.89–0.96) <0.001 0.96 (0.93–1.00) 0.063
Women 373 81 (21.7) 0.95 (0.89–1.00) 0.16 0.99 (0.92–1.06) 0.772
Mortality and/or heart failure hospitalization
KCCQ-OS
Total 1649 604 (36.6) 0.90 (0.88–0.93) <0.001 0.95 (0.93–0.97) <0.001
Men 1276 799 (37.4) 0.90 (0.88–0.92) <0.001 0.95 (0.93–0.97) <0.001
Women 373 127 (34) 0.89 (0.85–0.94) <0.001 0.95 (0.91–1.00) 0.060
EQ-5D VAS
Total 1649 604 (36.6) 0.95 (0.93–0.97) <0.001 0.97 (0.95–0.99) 0.004
Men 1276 799 (37.4) 0.95 (0.93–0.96) <0.001 0.97 (0.95–0.99) 0.012
Women 373 127 (34) 0.94 (0.9–0.98) 0.002 0.97 (0.93–1.01) 0.127
EQ-5D US
Total 1649 604 (36.6) 0.93 (0.9–0.96) <0.001 0.96 (0.94–0.99) 0.003
Men 1276 799 (37.4) 0.9 (0.88–0.93) <0.001 0.96 (0.93–0.99) 0.003
Women 373 127 (34) 0.92 (0.87–0.97) 0.002 0.97 (0.92–1.03) 0.308
CI, confidence interval; EQ-5D, EuroQoL 5 dimensions; HR, hazard ratio; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire overall score; US, utility score; VAS, visual
analogue scale.
improvement after treatment. Our study, conducted on a large
prospective HF cohort including both inpatients and outpatients,
with the specific aim of up-titrating ACEi/ARB and beta-blockers
according to recent ESC guidelines, shows that sex influences the
patients’ instantaneous QoL perception, but not QoL variations
over time. This finding remains consistent both when QoL is
evaluated with EQ-5D, a general health status survey that allows
the estimation of a health utility score particularly useful for
economic analyses, and with KCCQ, one of the questionnaires














. in HF.17 Even though its prospective cohort design does not allow
causation inference on the underlying reasons for the observed
QoL improvement, our study confirms that QoL benefit is equally
present in men and women when managed according to recent
ESC guidelines.
In the current study, all three baseline QoL measures were asso-
ciated with mortality, HF hospitalization, and the combined out-
come at univariable analysis. In multivariable analyses, KCCQ-OS
and EQ-5D VAS were independently associated with all outcomes,
while EQ-5D US only with mortality and the composite outcome.
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Table 3 C-statistic for different baseline quality of life measure-based models for predicting mortality, heart failure
hospitalization, and mortality and/or heart failure hospitalization
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Mortality
KCCQ-OS 0.650 0.016 – –
EQ-5D US 0.633 0.016 0.185 –
EQ-5D VAS 0.599 0.016 <0.001 0.025
Heart failure hospitalization
KCCQ-OS 0.629 0.015 – –
EQ-5D US 0.562 0.015 <0.001 –
EQ-5D VAS 0.574 0.015 <0.001 0.447
Mortality and/or heart failure hospitalization
KCCQ-OS 0.636 0.012 – –
EQ-5D US 0.587 0.012 <0.001 –
EQ-5D VAS 0.582 0.012 <0.001 0.674
EQ-5D, EuroQoL 5 dimensions; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire overall score; SE, standard error; US, utility score; VAS, visual analogue scale.
No significant interaction of sex was observed in any of these asso-
ciations. Even though QoL surveys are still not routinely adminis-
tered in clinical practice,9 they are frequently used as surrogate
endpoints in clinical trials, especially in phase 2 trials, and their use
in phase 3 trials beside morbidity and mortality is currently encour-
aged by regulatory authorities.8 The association with outcome of
patient-reported health status assessed with KCCQ6,7 and EQ-5D5
measures in HFrEF was already established. However, this is the
first study to our knowledge to specifically analyse sex differences
in the association between QoL and outcome. Sex differences in
HF have been overlooked for a long time, and clinical trials lead-
ing to drug approval in HFrEF enrolled predominantly men.2 Mainly
based on male-derived data, conclusions of clinical trials in HFrEF
may thus be male-biased. Notably, we recently showed that women
with HFrEF might even need lower doses of ACEi or ARBs and
beta-blockers than men to achieve lowest hazards of death or HF
hospitalization.24 The observation that QoL measures carry the
same prognostic meaning in women and men bears great impor-
tance for interpreting data from past trials, especially those of drugs
approved for symptom relief indication without a clear survival
benefit (e.g. digoxin, ivabradine), and to inform QoL survey use
in future clinical trials. On the other hand, the different prognos-
tic meaning of 6MWT, an objective measure of functional capacity,
towards mortality in men and women, is a hypothesis-generating
finding and warrants further investigation in other databases.
Although KCCQ and EQ-5D evaluate different aspects of HF
patients’ health status, KCCQ-OS showed the strongest associa-
tion with all outcomes, also in the long term (1–2 years), though
it conveyed no significant added prognostic value to the predic-
tive ability of the previously validated set of clinical and laboratory
variables in the BIOSTAT-CHF risk models.15 However, this finding
encourages the use of KCCQ both as surrogate endpoint in clinical
trials, as it reliably reflects patients’ health-related QoL and is inde-
pendently associated with long-term clinical outcomes, but also in





















































. Overall, the findings from this study highlight the importance of
evaluating patients’ subjective QoL perception in the clinical setting,
both in men and women, as it carries readily available prognostic
information. Furthermore, these findings are especially important
in the research setting, as they confirm the association of QoL
with outcome in a broad HF population managed according to
recent ESC guidelines, without any relevant interaction with sex
in its prognostic meaning despite the sex differences observed
in the overall QoL measures and the particular QoL domains.
Finally, the head-to-head comparison of the features of KCCQ-
and EQ-5D-derived measures provides important information for
planning future clinical trials.
Limitations
Our study has several potential limitations. First, this was a post-hoc
analysis even though carried out on a prospective HF cohort.
Secondly, patients enrolled in BIOSTAT-CHF were predominantly
Caucasian, thus limiting the generalizability of our findings to
other ethnicities. In third place, we included in our analysis only
patients that completed both KCCQ and EQ-5D questionnaires at
baseline, thus introducing a potential selection bias on a population
subset with less severe HF at baseline. Moreover, we focused on
HFrEF while many women with HF have preserved left ventricular
ejection fraction, and our study population included more men
than women, though this is very common in studies on HFrEF.
Finally, we compared a single generic and a single HF-specific QoL
questionnaire, as more QoL surveys within each category were not
available in our cohort.
Conclusions
While women with HFrEF had similar physician-assessed symp-
toms, they reported worse QoL than men. However, men and
women showed a similar improvement in QoL after 9-month
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Time-dependent receiver operating characteristic curves for different quality of life measure-based models for predicting
(A) mortality, (B) heart failure hospitalization, and (C) the composite outcome. EQ-5D, EuroQoL 5 dimensions; KCCQ, Kansas City
Cardiomyopathy Questionnaire; VAS, visual analogue scale.
follow-up. Baseline QoL was independently associated with sub-
sequent mortality and HF hospitalization, similarly in men and
women, with KCCQ-OS showing the strongest association with
outcome.
Supplementary Information
Additional supporting information may be found online in the














This work was supported by a grant from the European Commis-
sion [FP7-242209-BIOSTAT-CHF].
Conflict of interest: B.T.S. reports grants from the Dutch
Heart Foundation (2019 T094), during the conduct of this
study. J.P.F. is a consultant for Boehringer Ingelheim. M.M.
received personal honoraria for participation to trial commit-
tees, advisory boards or speeches at sponsored symposia from
Abbott Vascular, Amgen, AstraZeneca, Bayer, Vifor Pharma,
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Quality of life in men and women with heart failure 577
Servier, WindTree Therapeutics. All other authors have nothing
to disclose.
References
1. von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N,
Herrmann-Lingen C, Garfias Macedo T, Koziolek M, Noutsias M, Schulze PC,
Wachter R, Hasenfuß G, Laufs U. Improving exercise capacity and quality of
life using non-invasive heart failure treatments: evidence from clinical trials. Eur
J Heart Fail 2021;23:92–113.
2. Lam CS, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM,
Ky B, Santema BT, Sliwa K, Voors AA. Sex differences in heart failure. Eur Heart J
2019;40:3859–3868c.
3. Dewan P, Rørth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT,
Desai AS, Dickstein K, Køber L, Mogensen UM, Packer M, Rouleau JL, Solomon
SD, Swedberg K, Zile MR, McMurray JJ. Differential impact of heart failure with
reduced ejection fraction on men and women. J Am Coll Cardiol 2019;73:29–40.
4. Lesman-Leegte I, Jaarsma T, Coyne JC, Hillege HL, Van Veldhuisen DJ, Sander-
man R. Quality of life and depressive symptoms in the elderly: a comparison
between patients with heart failure and age- and gender-matched community
controls. J Card Fail 2009;15:17–23.
5. Ambrosy AP, Cerbin LP, DeVore AD, Greene SJ, Kraus WE, O’Connor CM,
Piña IL, Whellan DJ, Wojdyla D, Wu A, Mentz RJ. Aerobic exercise training
and general health status in ambulatory heart failure patients with a reduced
ejection fraction – findings from the Heart Failure and A Controlled Trial
Investigating Outcomes of Exercise Training (HF-ACTION) trial. Am Heart J
2017;186:130–138.
6. Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L,
Swedberg K. Heart rate reduction with ivabradine and health related quality of
life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J
2011;32:2395–2404.
7. Pokharel Y, Khariton Y, Tang Y, Nassif ME, Chan PS, Arnold SV, Jones PG, Spertus
JA. Association of serial Kansas City Cardiomyopathy Questionnaire assessments
with death and hospitalization in patients with heart failure with preserved and
reduced ejection fraction: a secondary analysis of 2 randomized clinical trials.
JAMA Cardiol 2017;2:1315–1321.
8. Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, Lewis EF,
Abraham WT, Teerlink J, Walsh M, Heidenreich P, Bozkurt B, Starling RC,
Solomon S, Felker GM, Butler J, Yancy C, Stevenson LW, O’Connor C, Unger E,
Temple R, McMurray J. Endpoints in heart failure drug development: history and
future. JACC Heart Fail 2020;8:429–440.
9. Rumsfeld JS, Alexander KP, Goff DC Jr, Graham MM, Ho PM, Masoudi FA,
Moser DK, Roger VL, Slaughter MS, Smolderen KG, Spertus JA, Sullivan MD,
Treat-Jacobson D, Zerwic JJ. Cardiovascular health: the importance of measuring
patient-reported health status: a scientific statement from the American Heart
Association. Circulation 2013;127:2233–2249.
10. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities
using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes
2010;8:13.
11. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation
of the Kansas City Cardiomyopathy Questionnaire: a new health status measure
for heart failure. J Am Coll Cardiol 2000;35:1245–1255.
12. Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P,
Hillege HL, Lang CC, Ter Maaten JM, Ng L, Ponikowski P, Samani NJ, van
Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M. A systems BIOlogy Study
to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline
characteristics of BIOSTAT-CHF. Eur J Heart Fail 2016;18:716–726.
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K,
Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip
GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten
FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F,
Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R,
Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T,
Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A,
Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P,












































































. FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW,
Orn S, Parissis JT, Ponikowski P. ESC Guidelines for the diagnosis and treatment
of acute and chronic heart failure 2012: the Task Force for the diagnosis and
treatment of acute and chronic heart failure 2012 of the European Society of
Cardiology. Developed in collaboration with the Heart Failure Association (HFA)
of the ESC. Eur J Heart Fail 2012;14:803–869.
14. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW,
Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure 2008: the
Task Force for the diagnosis and treatment of acute and chronic heart failure
2008 of the European Society of Cardiology. Developed in collaboration
with the Heart Failure Association of the ESC (HFA) and endorsed by the
European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:
933–989.
15. Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P,
Ng LL, Metra M, Ter Maaten JM, Lang CC, Hillege HL, van der Harst P,
Filippatos G, Dickstein K, Cleland JG, Anker SD, Zwinderman AH. Development
and validation of multivariable models to predict mortality and hospitalization in
patients with heart failure. Eur J Heart Fail 2017;19:627–634.
16. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P,
McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS. Monitoring clinical
changes in patients with heart failure: a comparison of methods. Am Heart J
2005;150:707–715.
17. Kelkar AA, Spertus J, Pang P, Pierson RF, Cody RJ, Pina IL, Hernandez A, Butler J.
Utility of patient-reported outcome instruments in heart failure. JACC Heart Fail
2016;4:165–175.
18. Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P, Powers E,
Rich S, Hackshaw B, Chiaramida A, Rouleau JL, Fisher MB, Pigeon J, Rush JE.
Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized
trial of lisinopril versus captopril in the treatment of congestive heart failure. The
Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll
Cardiol 1989;13:1240–1247.
19. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S,
Schron E, Shumaker SA, Sheffield LT. Quality of life among 5,025 patients with left
ventricular dysfunction randomized between placebo and enalapril: the Studies
of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol
1994;23:393–400.
20. Majani G, Giardini A, Opasich C, Glazer R, Hester A, Tognoni G, Cohn JN,
Tavazzi L. Effect of valsartan on quality of life when added to usual therapy
for heart failure: results from the Valsartan Heart Failure Trial. J Card Fail
2005;11:253–259.
21. O’Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL,
Young JB, Michelson EL, Ostergren J, Carlsson J, Olofsson B, McMurray J,
Yusuf S, Swedberg K, Pfeffer MA. Patient perception of the effect of treatment
with candesartan in heart failure. Results of the Candesartan in Heart Failure:
Assessment of Reduction in Mortality and Morbidity (CHARM) Programme. Eur
J Heart Fail 2005;7:650–656.
22. Gallanagh S, Castagno D, Wilson B, Erdmann E, Zannad F, Remme WJ,
Lopez-Sendon JL, Lechat P, Follath F, Höglund C, Mareev V, Sadowski Z,
Seabra-Gomes RJ, Dargie HJ, McMurray JJ. Evaluation of the functional status
questionnaire in heart failure: a sub-study of the Second Cardiac Insufficiency
Bisoprolol Survival Study (CIBIS-II). Cardiovasc Drugs Ther 2011;25:77–85.
23. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J,
Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus
KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J,
Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release
metoprolol on total mortality, hospitalizations, and well-being in patients with
heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Con-
gestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:
1295–1302.
24. Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V,
Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten
JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen
DJ, Meyer S, Lam CS, Voors AA; ASIAN-HF Investigators; Identifying optimal
doses of heart failure medications in men compared with women: a prospective,
observational, cohort study. Lancet 2019;394:1254–1263.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
